Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDI0382 PK in renal impairment
NCT03235375Phase 1Completed
- Sponsor
- MedImmune
- Start
- Oct 2017
- Primary completion
- Apr 2018
- Modality
- Peptides
- Countries
- 2
01
Overview
Phase 1, open-label trial of cotadutide in type 2 diabetes mellitus (T2DM), obesity and Nonalcoholic steatohepatitis (NASH) (4 arms), sponsored by MedImmune. Primary endpoints: Maximum Observed Concentration and Area under the Concentration Time Curve. Started Oct 2017; status: completed.
02
Drugs
cotadutide
03
Conditions
type 2 diabetes mellitus (T2DM)obesityNonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT03235375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03235375.